Amyotrophic Lateral Sclerosis (ALS), is a fatal neurodegenerative disorder, with TDP-43 1 6 inclusions as a major pathological hallmark. Using a Drosophila model of TDP-43 proteinopathy 1 7
Our findings that TDP-43 expression in motor neurons alters glycolysis could be 1 4 4 explained by and effect on glucose flux. To evaluate the levels of glucose in motor neurons, in 1 4 5 the context of TDP-43 proteinopathy, we used a genetically encoded, FRET based, glucose 1 4 6 sensor, FLII12Pglu-700μδ6 (Takanaga, Chaudhuri, and Frommer 2008; Fehr et al. 2003) . The The alterations in glucose metabolism we have uncovered here could be a direct 1 7 2 consequence of TDP-43 proteinopathy or alternatively, could reflect a coping mechanism. To 1 7 3 distinguish between these two scenarios, we fed TDP-43 expressing flies a high glucose diet.
7 4
As we have previously shown, the neuronal or glial expression of TDP-43 WT or TDP-43 G298S 1 7 5 caused locomotor defects as indicated by increased larval turning time compared to controls 1 7 6 (Estes et al. 2011; Estes et al. 2013) . Of note, a high glucose diet increased the larval turning 1 7 7 time of control larvae, consistent with previous reports that high sugar intake induces insulin 1 7 8 resistance and obesity in flies (Musselman et al. 2011; Na et al. 2013) . In contrast, a high 1 7 9 glucose diet improved the larval locomotor defect caused by either neuronal, or glial expression 1 8 0 of TDP-43 ( Fig. 4A and Supplemental Fig. 4A ). Interestingly, we found that increasing the 1 8 1 concentration of glucose five-fold or higher rescued locomotor phenotypes caused by TDP-43 1 8 2 while no improvement was observed when glucose is only increased by two-fold (Supplemental 1 8 3 Fig. 4A ). Next, we examined the effect of glucose on lifespan and found that the reduced 1 8 4 survival caused by neuronal or glial expression of TDP-43 WT or TDP-43 G298S was also 1 8 5 significantly improved by feeding Drosophila a high sugar (HS) versus a regular sugar (RS) diet 1 8 6 (23.5 days for TDP-43 WT on RF and 53 days for TDP-43 WT on HS, P value = <0.0001; 14.5 days for 1 8 7 TDP-43 G298S on RS and 41 days for TDP-43 G298S HS, P value = <0.0001 ; Fig. 4B Larval turning and lifespan assays for Drosophila expressing GLUT-3 on its own or with TDP-1 9 7 43, as indicated. At least 30 larvae were tested in larval turning assays and on average 20 1 9 8 adults were assayed for survival. Kruskal-Wallis test and Log-rank (Mantel-Cox) test was used 1 9 9 to determine statistical significance for larval turning and survival curve respectively. * -p < .05, 2 0 0 ** -p<0.01, *** -p<0.001. of mammalian neurons, and has a high capacity for glucose (Ferreira, Burnett, and Rameau 2 0 9 2011). Co-expression of GLUT-3 and TDP-43 WT or TDP-43 G298S , in either motor neurons or glia 2 1 0 cells, improved the locomotor deficits caused by TDP-43 expression alone ( Fig. 4C ). Moreover, 2 1 1 GLUT-3 expression in neurons improved the locomotor ability of adult flies expressing TDP-2 1 2 43 WT or TDP-43 G298S (as measured by negative geotaxis assays, Supplemental Figure 4D ).
1 3
When using the standard log-rank test for analyzing the survival data, lifespan was significantly 2 1 4 increased when GLUT-3 was co-expressed with TDP-43 G298S in motor neurons, but not glial 2 1 5 cells (18 days for TDP-43 G298S and 30 days for TDP-43 G298S , P value = <0.0001). However, when 2 1 6 using the Mantel-Cox test, which weighs earlier deaths more significantly, we found that GLUT-2 1 7 3 overexpression increases lifespan when TDP-43 G298S is expressed in glial cells (43.5 days vs 2 1 8 51.5 days, P value = 0.015**). GLUT-3 had no effect on lifespan when TDP-43 WT was expressed 2 1 9 in either motor neurons or glia. These findings suggest that increased glucose availability is 2 2 0 protective in both motor neurons and glia but to a different extent that likely reflects different 2 2 1 metabolic capabilities of the two cell types.
2
Although GLUT-3 is the predominant glucose transporter in the brain, recently, the 2 2 3 human glucose transporter GLUT-4, an insulin dependent glucose transporter expressed 2 2 4 primarily in muscle has been shown to localize to the plasma membrane to support synaptic 2 2 5 activity (Ashrafi et al. 2017) . To test whether GLUT-4 also modulates TDP-43 proteinopathy, we 2 2 6 co-expressed GLUT-4 and TDP-43 in either motor neurons or glia. Similar to GLUT-3, co-2 2 7 overexpression of GLUT-4 and TDP-43 WT or TDP-43 G298S , in either motor neurons or glial cells, 2 2 8 improved the locomotor deficits caused by TDP-43 expression alone (Supplemental Figure 4C ).
9
Interestingly, lifespan was not significantly increased for either glial or motor neuron expression, 2 3 0 suggesting that constitutive increase in glucose availability mediated by GLUT3 is more potent 2 3 1 in suppressing TDP-43 proteinopathy in flies (Supplemental Figure 4C ). Notably, while TDP-43 2 3 2 overexpression in muscle causes larval turning phenotypes, co-overexpression of either GLUT-2 3 3 3 or GLUT-4 in muscle does not mitigate TDP-43 dependent locomotor deficits, suggesting that 2 3 4 the primary metabolic defect lies in the nervous system (Supplemental Figure 4C ).
3 5
TDP-43 dependent defects at the neuromuscular junction are rescued by GLUT-3 2 3 6
We previously described defects at the Drosophila neuromuscular junction (NMJ) caused by rescued locomotor defects to control levels (P value = 0.003 for TDP-43 WT and P value <0.001 for 2 7 2 TDP-43 G298S , Fig. 6A ). In contrast, PFK RNAi knock-down had no significant effect on larval 2 7 3 turning when expressed in motor neurons alone (53% knock-down, P value = 0.04, see Materials 2 7 4 and Methods). However, when PFK was knocked down by RNAi in the context of TDP-43 2 7 5 proteinopathy we found that it significantly increased larval turning times for TDP-43 WT albeit it 2 7 6 had no effect on TDP-43 G298S (P value < 0.001 for TDP-43 WT and P value = 0.767 for TDP-43 G298S , 2 7 7 Fig. 6B ). One possible interpretation for this variant dependent effect is that the metabolic deficit 2 7 8 of TDP-43 G298S is so severe that it may be difficult to exacerbate by further altering energy 2 7 9 metabolism. Of note, a second PFK RNAi line (y(1) sc[*] v(1); P{y[+t7.7] 2 8 0 v[+t1.8]=TRiP.HMS01324}attP2) was tested, but was lethal when expressed in motor neurons.
8 1
Similar to the experiments with motor neurons, the over-expression of PFK in glial cells 2 8 2 causes a locomotor defect, while the expression of two independent PFK RNAi lines has no 2 8 3 effect on locomotor activity as determined by larval turning assays (Supplemental Fig. 6 ). When 2 8 4 PFK is co-expressed in glial cells with TDP-43 WT there is a slight but not statistically significant It is widely known that ALS patients display gross metabolic dysregulation described as that just as in flies, PFK, the rate limiting step in glycolysis, is significantly upregulated (Fig. 2) .
1 2
Interestingly, metabolic profiling in flies also suggests increased glycolytic input into the pentose 3 1 3 phosphate pathway ( Supplemental Table 1 ), which provides a mechanism for countering 3 1 4 oxidative stress via increased NADPH production (Kruger and von Schaewen 2003). Supporting 3 1 5 this possibility are our findings that G6PD, the rate limiting enzyme of the pentose phosphate 3 1 6 pathway is upregulated in fly and human ALS ventral and spinal cords, respectively (Fig. 2) .
1 7
Oxidative stress is a well-established ALS manifestation (Barber and Shaw 2010) and the most 3 1 8 recent FDA approved drug for treating ALS patients, Radicava is aimed at countering this 3 1 9 aspect of the disease (Cruz 2018). Collectively, molecular and metabolic alterations identified in 3 2 0 the fly validate in patient derived motor neurons and spinal cords, albeit the magnitude of the 3 2 1 changes found in human ALS tissues is often more dramatic and, at some level, more 3 2 2 comparable with mutant TDP-43 dependent phenotypes in flies. These findings highlight the 3 2 3 predictive power of the fly model and its relevance to studying disease pathomechanisms in 3 2 4 humans.
2 5
Using a genetically encoded glucose sensor we show that TDP-43 G298S expressing 3 2 6 motor neurons have increased capacity to import glucose (Fig. 3) . This is consistent with 3 2 7 increased glycolysis and its end product, pyruvate. It is unclear why despite finding that 3 2 8 pyruvate is also increased in motor neurons overexpressing TDP-43 WT , we could not detect 3 2 9 higher glucose uptake than in controls, although this is consistent with PFK transcript levels 3 3 0 trending up, yet not reaching significance in our data set (Fig. 2) . A possible explanation is that 3 3 1 while our model is based on TDP-43 expression specifically in motor neurons or glia, the 3 3 2 metabolite profiling was performed on whole larvae and captured non-cell autonomous 
4 0
In an effort to address this question, we first increased glucose availability in Drosophila 3 4 1 by raising the dietary concentration of glucose (5-10 X higher than normal levels in standard fly 3 4 2 food), which mitigates locomotor defects and increases lifespan in ALS flies while making wild-3 4 3 type larvae sluggish (Fig. 3) . Interestingly, a high sugar diet only mitigates locomotor defects 3 4 4 when TDP-43 is expressed in motor neurons or glia but not muscles, indicating that the primary 3 4 5 metabolic defect lies in the nervous system and that muscles do not benefit from increased 3 4 6 glucose availability ( Fig. 4 and Supplemental Figs. 4B and 4C ). This is somewhat surprising 3 4 7
given that muscles normally rely on glycolysis for ATP production but is also consistent with 3 4 8 findings that in ALS, muscles switch to primarily using lipids and not glucose for energy 
5 0
This systemic approach, however, does not provide information on which cells 3 5 1 specifically benefit from increased glucose availability. To answer this question, we intervened showed that both GLUT-3 and GLUT-4 rescued locomotor dysfunction of TDP-43 expressing 3 5 5 larvae in the nervous system, but not in muscles ( Fig. 4 and Supplemental Figs. 4B and 4C) 3 5 6 confirming our findings from high sugar feedings. Furthemore, our findings that overexpression 3 5 7 of either GLUT-3 or GLUT-4 can help mitigate specific ALS-like phenotypes in flies are 3 5 8 consistent with recent reports that both GLUT-3 and GLUT-4 are required at synapses to 3 5 9 regulate activity (Ashrafi et al. 2017; Ferreira, Burnett, and Rameau 2011) . Together, our dietary 3 6 0 intervention and GLUT-3/4 overexpression experiments indicate that increased glucose 3 6 1 availability in motor neurons and glia confers protection in models of TDP-43 proteinopathy, in a 3 6 2 cell type dependent manner.
6 3
A possible explanation for why increased glucose availability improves defects caused 3 6 4 by TDP-43 proteinopathy is that cells are actively consuming glucose to increase glycolytic flux.
6 5
A recent study using vertebrate cell lines suggests that glycolytic flux depends on four key 3 6 6 steps. They include: 1) glucose uptake by glucose transporters, 2) hexokinase levels, 3) PFK 3 6 7 levels (and associated enzymes), and 4) lactate export, but not other enzymes or steps involved 3 6 8 in glycolysis (Tanner et al. 2018 ). The co-over-expression of PFK mitigates TDP-43 defects in 3 6 9 flies, and is consistent with our GLUT-3 over-expression experiments (Fig. 6) . Surprisingly, PFK 3 7 0 transcript levels were higher in human ALS post-mortem tissues compared to controls, however 3 7 1 protein levels in total tissue homogenates were not significantly increased despite trending 3 7 2 upwards (data not shown). Nevertheless, our findings of increased PFK mRNA levels in flies 3 7 3 and human tissues, and the genetic interaction experiments support the notion that glycolysis is 3 7 4 increased in ALS as a compensatory mechanism (see Figure 7 for model).
7 5
The fact that neurons would compensate deficits in cellular energetics through 3 7 6 increasing glycolysis makes sense in the light of well-established defects in mitochondrial 3 7 7 function. TDP-43 has been previously shown to localize to the inner mitochondrial membrane of 
